This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Wylie, M. E. Articles by Reynolds, C. F. Search for Related Content PubMed PubMed Citation Articles by Wylie, M. E. Articles by Reynolds, C. F. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Anxiety Obsessive-Compulsive Disorder Panic Disorder Social Bookmarking                         What's this?

Fluvoxamine Pharmacotherapy of Anxiety Disorders in Later Life: Preliminary Open-Trial Data

Mark D. Miller, MD

M. Katherine Shear, MD

John T. Little, MD

Benoit H. Mulsant, MD

Bruce G. Pollock, MD, PhD

Charles F. Reynolds, MD

The authors present data from an open trial of fluvoxamine (median daily dosage: 200 mg) in the treatment of generalized anxiety disorder, panic disorder, and obsessive-compulsive disorder in 19 older outpatients (mean age = 66.8). Of the 12 subjects completing the 21-week trial, 8 achieved a good response (50% reduction in symptom measures) and 7 were rated as much or very much improved. Fluvoxamine pharmacotherapy also had a significant effect in reducing comorbid depressive symptoms and in increasing levels of functioning. These data support the effectiveness of fluvoxamine in older subjects with anxiety disorders (particularly generalized anxiety disorder) and warrant further double-blind, placebo-controlled evaluation. (J Geriatr Psychiatry Neurol 2000; 13:43—48).

Journal of Geriatric Psychiatry and Neurology, Vol. 13, No. 1, 43-48 (2000)
DOI: 10.1177/089198870001300107


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				References PsychiatryOnline CME, May 1, 2007; 2007(1): 2 - 2. [Full Text]

				E. J. Lenze, B. H. Mulsant, M. K. Shear, M. A. Dew, M. D. Miller, B. G. Pollock, P. Houck, B. Tracey, and C. F. Reynolds III Efficacy and Tolerability of Citalopram in the Treatment of Late-Life Anxiety Disorders: Results From an 8-Week Randomized, Placebo-Controlled Trial Am J Psychiatry, January 1, 2005; 162(1): 146 - 150. [Abstract] [Full Text] [PDF]